title: A comparison of health utility measures for the evaluation of multiple sclerosis treatments.
abstract: OBJECTIVE
  To evaluate the practical application and psychometric properties of three health utility measures in a sample of MS patients with a broad range of neurological disability as measured by the Extended Disability Status Scale (EDSS).
  
  
  METHODS
  Patients randomly selected from two MS clinic registries were assessed using standard clinical methods and completed three generic measures of health utility (EQ-5D, HUI Mark III, SF-6D). The proportion of missing data, test/retest reliability, and construct validity of each health utility measure were examined.
  
  
  RESULTS
  The assessments were completed by 187 patients. Less than 10% of data were missing for the subscales of the SF-6D (< 3.2%), HUI Mark III (<1.6%), and EQ-5D (< or =7.5%). Severely disabled patients were more likely to omit physical function questions for the SF-6D (20%), and EQ-5D (43%). Retest reliability for the SF-6D (ICC = 0.83), EQ-5D (ICC = 0.81), and HUI Mark III (ICC = 0.87) were adequate for population surveys. Correlations between assessment of clinical function and each health utility measure were strongest for the HUI Mark III (HUI Mark III EDSS rho = -0.77, HUI Mark III ambulation index rho = -0.76, HUI Mark III timed 25 foot walk rho = -0.73, HUI Mark III nine hole peg test rho = -0.65).
  
  
  CONCLUSIONS
  The health utility measures were generally feasible and reliable but the HUI Mark III demonstrated highest concordance with the EDSS across the full range of neurological disability. Of the three measures studied, the HUI Mark III may be the most appropriate for cost effectiveness evaluations of MS therapies.
authors.affiliation: Abbie J. Lane Building, Queen Elizabeth II Health Sciences Centre, Veterans Memorial Lane, Halifax, Nova Scotia B3H 2E3, Canada. john.fisk@cdha.nshealth.ca
authors.forename: J D
authors.initials: JD
authors.lastname: Fisk
authors.forename: M G
authors.initials: MG
authors.lastname: Brown
authors.forename: I S
authors.initials: IS
authors.lastname: Sketris
authors.forename: L M
authors.initials: LM
authors.lastname: Metz
authors.forename: T J
authors.initials: TJ
authors.lastname: Murray
authors.forename: K J
authors.initials: KJ
authors.lastname: Stadnyk
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003430:Cross-Sectional Studies; D004185:Disability Evaluation; D005260:Female; D000068717:Glatiramer Acetate; D006305:Health Status Indicators; D006801:Humans; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy*; D010455:Peptides / Q000627:therapeutic use*; D011594:Psychometrics; D011788:Quality of Life; D015203:Reproducibility of Results; D016896:Treatment Outcome
chemical_list: D000276:Adjuvants, Immunologic; D010455:Peptides; D000068576:Interferon beta-1b; D000068717:Glatiramer Acetate; D016899:Interferon-beta; D000068556:Interferon beta-1a